<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0002959'>Microalbuminuria</z:mp> is one of the strongest predictors of both adverse renal and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) outcomes in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Although measurement of urinary albumin excretion (UAE) is widely recommended, limited data are available to suggest that reducing UAE translates into a reduction in long-term cardiovascular mortality, particularly among patients without overt <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, who constitute most patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> worldwide </plain></SENT>
<SENT sid="2" pm="."><plain>We assessed whether changes in the UAE at 1 year were associated with cardiovascular mortality in 393 patients with <z:hpo ids='HP_0000822'>hypertension</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> during a 10-year period </plain></SENT>
<SENT sid="3" pm="."><plain>On univariate analysis, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> history, age, <z:mp ids='MP_0002055'>diabetes</z:mp> duration, and change in UAE at 1 year were associated with cardiovascular mortality risk (hazard ratio 2.60 for those with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> history, 95% confidence interval [CI] 1.47 to 4.62; hazard ratio 1.59 per 10 years of <z:mp ids='MP_0002055'>diabetes</z:mp> duration, 95% CI 1.12 to 2.25; and hazard ratio 1.49 per log UAE increase, 95% CI 1.13 to 1.96) </plain></SENT>
<SENT sid="4" pm="."><plain>In a stepwise Cox regression model that included baseline UAE and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> history, the 10-year predicted mortality of those with a decrease in UAE of 2 logs at 1 year was 4.7% (95% CI 1.4% to 7.8%) </plain></SENT>
<SENT sid="5" pm="."><plain>For those with an increase in UAE of 2 logs at 1 year, it was 24.5% (95% CI 10.1% to 36.5%) </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, these data support current guideline recommendations to screen for UAE in <z:hpo ids='HP_0000001'>all</z:hpo> patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, even in the absence of <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, and suggest that serial UAE measurements even after the initiation of <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> therapy has prognostic value independent of traditional <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> </plain></SENT>
</text></document>